User Profile

Name: Jennifer Hogan
Member Since: October 11th, 2011
Member Name: jenhogan
Last Logged In: March 29th, 2012


Jennifer N. Hogan
1406 Henry St., Apt. M, Berkeley, CA 94709
cell: (650) 430-8741
University of California, Davis Epidemiology Ph.D. Candidate Sept 2007-present
Gonzaga University Bachelor of Science: Biology Minor: Sociology May 2005
Dean’s List: Spring 2004, Fall 2004, Spring 2005
Technical Skills
Math and Computer Skills: SAS Statistical Software, ArcGIS, SaTScan, Study Director, GraphPad Prism, Word,
PowerPoint, Excel, Adobe Photoshop, Adobe Illustrator
Laboratory Skills: RNA isolation and purification, gel electrophoresis, DNA and protein isolation, PCR,
immunomagnetic separation (IMS), fecal floatation
Slide Preparation and Staining: Microtome and water-bath techniques, Cryostat usage, H&E,
immunohistochemistry, direct fluorescent antibody staining (DFA)
In Vivo: intraperitoneal, intravenous, subcutaneous and oral dosing using mouse models; tumor and weight
measurements, terminal cardiac blood collection, gross necropsy, organ and tumor collection, experience
with athymic nude, SCID, NIH3, and conventional mouse strains
Tissue Culture: maintaining stable cell lines, cell counts, sterile technique, cell implantation into mouse models
Graduate Student Researcher
Veterinary Medicine: PMI, UC Davis, CA (02/08-present)
• As a California Sea Grant Trainee, evaluated the efficacy of wetlands in protozoal removal through
developing methodology to examine protozoa transport and surveying protozoa contamination in
wetlands through sample collection in the field, IMS and DFA processing, and microscopy analysis.
• Collaborated with the Mountain Gorilla Veterinary Project in Rwanda to evaluate fecal protozoal
transmission in sympatric species in the Virunga National Park.
• Analyzed protozoa counts with applied Poisson and Negative Binomial regression methods using SAS
and examined spatial relationships using SatScan and ArcGIS programming.
Staff Research Associate I,
Pharmacology Department, Sunesis Pharmaceuticals, South San Francisco, CA (06/05-08/07)
• Performed in vivo studies to support pre-clinical Aurora Kinase Inhibitor program.
• Maintained a library of human cancer cell lines and directed implantation of cancer cell lines for in vivo
studies in athymic nude mice.
• Performed intraperitoneal (IP), intravenous (IV), and oral (PO) dosing of athymic nude mice, tumor and
terminal blood collection, gross necropsy, and tumor volume and weight measurements for xenograft,
growth curve, and target modulation studies.
• Developed a process for immunohistochemical tumor sample analysis to support development projects.
Research Laboratory Intern,
Molecular Oncology Department, Genentech, South San Francisco, CA (05/04-08/04)
• Maintained populations of stable cell lines.
• Monitored tumor growth size and weight of athymic nude mice.
• Isolated and purified RNA, DNA, and protein for analysis.
Field Assistant,
Lumina Technologies, Santa Rosa, CA (07/03-05/05)
• Evaluated sites for possible environmental contamination.
• Compiled information for Environmental Impact Reports through site surveys and toxic record and
environmental record searches.
• Collected sound and light level measurement data, and performed biology and botany surveys.
Biology Teaching Experience,
Gonzaga University, Spokane, WA
Biology Tutor for Biology 101 and 102 (09/03-05/05)
• Clarified and identified questions students had in these classes and facilitated study groups.
• Helped students’ comprehension and encouraged them to adopt successful study strategies.
Biology Lab Teaching Assistant for Biology 101 and 102 (01/03-05/05)
• Instructed students in various laboratory skills essential to biological and ecological study.
• Created weekly quizzes, and was in charge of in-class assignments and grading.
Awards Received
UC Davis and Humanities Graduate Research Fellowship, 2011-2012
Graduate Group of Epidemiology Fellowship, 2011-2012
Graduate Student Travel Award 2011
Wildlife Health Center Fellowship 2010-2011
Graduate Group of Epidemiology Block Grant, 2007, 2008, 2009, 2010
Published Literature
Epidemiology of Cryptosporidium, Giardia, and fecal indicator bacteria in coastal California wetland ecosystems.
Hogan JN, Daniels ME, Watson FG, Conrad PA, Oates SC, Miller MA, Hardin D, Byrne BA, Dominik C,
Melli A, Jessup DA, Miller WA. In preparation.
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, Harris SO, Hashash A,
Hoch U, Hogan JN, Howlett AR, Jacobs JW, Lam JW, Ritchie SC, Romanowski MJ, Silverman JA, Stockett
DE, Teague JN, Zimmerman KM, Taverna P. Cancer Chemother Pharmacol. 2009 Aug 65(4):707-17.
The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy
with microtubule-targeted agents in a colon carcinoma model. VanderPorten EC, Taverna P, Hogan JN,
Ballinger MD, Flanagan WM, Fucini RV. Mol Cancer Ther. 2009 Apr;8(4):930-9.
Abstracts Presented
Giardia in Sympatric Wildlife in Volcanoes National Park, Rwanda. Hogan J, Hassell J, Noheri, JB, Ramer J,
Cranfield M, Miller W, Gilardi K. Wildlife Disease Association Annual Meeting: Quebec City, Canada,
August 14-19, 2011
Waterborne Protozoal Removal by Coastal California Wetlands. Hogan J, Daniels M, Watson F, Conrad P,
Miller, W. American Society of Parasitology Annual Meeting: Anchorage, AK, June 1-4, 2011.
Reaching across disciplines to form a one health team using the Mountain Gorilla One Health Program
(MGOHP) case study. Hogan J, Harris L. Global Health: Breaking Borders and Boundaries: Davis, CA,
April 9, 2011.
Waterborne Protozoal Removal by Coastal California Wetlands. Hogan J, Daniels M, Watson F, Conrad P,
Miller, W. EPA National Beach Conference: Miami, FL, March 14-17, 2011.
SNS-314, a selective Aurora kinase inhibitor with potent, pre-clinical anti-tumor activity, shows broad
therapeutic potential in combination with standard chemotherapeutics and synergy with microtubule
targeted agents. E. Chan, R. Fucini, K. Zimmerman, M. Bui, J. Hogan, M. Jackson, P. Taverna, M.
Ballinger, A. Howlett, M. Flanagan. European Cancer Conference, ECCO: Barcelona, Spain, September 23-
27, 2007.
SNS-314, a potent inhibitor of Aurora kinases, shows broad anti-tumor activity and dosing flexibility in vivo.
Jennifer N. Hogan, Jeffrey L. Kumer, Jennifer P. Arbitrario, Ute Hoch, Jeffrey A. Silverman, Anthony R.
Howlett and Pietro Taverna. International Symposium on Targeted Anticancer Therapies: Amsterdam, the
Netherlands, March 8-10, 2007.
SNS-314, a novel small-molecule Aurora kinase inhibitor, induces cell cycle defects and potently suppresses
tumor growth. K. Gamo, B. Belmont, D. Stockett, B.T. Tangonan, M.J. Romanowski, W. Lew, S. Baskaran,
C. Yu, E. Hanan, J. Oslob, M. Bui, M. Zhong, S. Heumann, D. Allen, W. Shen, J. Hogan, J. Kumer, A.
Howlett, T. O’Brien, W.M. Flanagan, Keystone Symposia, Molecular Targets for Cancer (X3): Whistler,
British Columbia, March 18-23, 2007.